vs
牛津地产（IIPR）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是牛津地产的1.0倍（$69.8M vs $66.7M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 47.8%，领先336.3%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -13.1%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -6.0%）
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
IIPR vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.0倍
$66.7M
营收增速更快
RIGL
高出34.3%
-13.1%
净利率更高
RIGL
高出336.3%
47.8%
两年增速更快
RIGL
近两年复合增速
-6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.7M | $69.8M |
| 净利润 | $31.8M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 47.8% | 33.2% |
| 净利率 | 47.8% | 384.0% |
| 营收同比 | -13.1% | 21.2% |
| 净利润同比 | -20.4% | 1769.2% |
| 每股收益（稀释后） | $1.07 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IIPRRIGL
| Q4 25 | $66.7M | $69.8M | ||
| Q3 25 | $64.7M | $69.5M | ||
| Q2 25 | $62.9M | $101.7M | ||
| Q1 25 | $71.7M | $53.3M | ||
| Q4 24 | $76.7M | $57.6M | ||
| Q3 24 | $76.5M | $55.3M | ||
| Q2 24 | $79.8M | $36.8M | ||
| Q1 24 | $75.5M | $29.5M |
净利润IIPRRIGL
| Q4 25 | $31.8M | $268.1M | ||
| Q3 25 | $29.3M | $27.9M | ||
| Q2 25 | $26.0M | $59.6M | ||
| Q1 25 | $31.1M | $11.4M | ||
| Q4 24 | $40.0M | $14.3M | ||
| Q3 24 | $40.2M | $12.4M | ||
| Q2 24 | $42.0M | $-1.0M | ||
| Q1 24 | $39.4M | $-8.2M |
毛利率IIPRRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率IIPRRIGL
| Q4 25 | 47.8% | 33.2% | ||
| Q3 25 | 45.5% | 40.9% | ||
| Q2 25 | 45.9% | 60.1% | ||
| Q1 25 | 47.4% | 23.9% | ||
| Q4 24 | 54.7% | 28.9% | ||
| Q3 24 | 54.8% | 25.4% | ||
| Q2 24 | 53.1% | 1.2% | ||
| Q1 24 | 55.7% | -23.6% |
净利率IIPRRIGL
| Q4 25 | 47.8% | 384.0% | ||
| Q3 25 | 45.3% | 40.2% | ||
| Q2 25 | 41.4% | 58.6% | ||
| Q1 25 | 43.3% | 21.5% | ||
| Q4 24 | 52.2% | 24.9% | ||
| Q3 24 | 52.6% | 22.5% | ||
| Q2 24 | 52.6% | -2.8% | ||
| Q1 24 | 52.3% | -27.9% |
每股收益（稀释后）IIPRRIGL
| Q4 25 | $1.07 | $14.11 | ||
| Q3 25 | $0.97 | $1.46 | ||
| Q2 25 | $0.86 | $3.28 | ||
| Q1 25 | $1.03 | $0.63 | ||
| Q4 24 | $1.35 | $0.82 | ||
| Q3 24 | $1.37 | $0.70 | ||
| Q2 24 | $1.44 | $-0.06 | ||
| Q1 24 | $1.36 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $47.6M | $155.0M |
| 总债务越低越好 | $393.7M | $52.5M |
| 股东权益账面价值 | $1.8B | $391.5M |
| 总资产 | $2.4B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.21× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资IIPRRIGL
| Q4 25 | $47.6M | $155.0M | ||
| Q3 25 | $41.9M | $137.1M | ||
| Q2 25 | $104.9M | $108.4M | ||
| Q1 25 | $133.3M | $77.1M | ||
| Q4 24 | $151.2M | $77.3M | ||
| Q3 24 | $172.4M | $61.1M | ||
| Q2 24 | $160.9M | $49.1M | ||
| Q1 24 | $173.5M | $49.5M |
总债务IIPRRIGL
| Q4 25 | $393.7M | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益IIPRRIGL
| Q4 25 | $1.8B | $391.5M | ||
| Q3 25 | $1.9B | $117.6M | ||
| Q2 25 | $1.9B | $81.9M | ||
| Q1 25 | $1.9B | $18.6M | ||
| Q4 24 | $1.9B | $3.3M | ||
| Q3 24 | $1.9B | $-14.6M | ||
| Q2 24 | $1.9B | $-29.9M | ||
| Q1 24 | $2.0B | $-31.7M |
总资产IIPRRIGL
| Q4 25 | $2.4B | $513.6M | ||
| Q3 25 | $2.3B | $242.5M | ||
| Q2 25 | $2.3B | $206.7M | ||
| Q1 25 | $2.4B | $176.0M | ||
| Q4 24 | $2.4B | $164.0M | ||
| Q3 24 | $2.4B | $139.4M | ||
| Q2 24 | $2.4B | $128.4M | ||
| Q1 24 | $2.4B | $126.5M |
负债/权益比IIPRRIGL
| Q4 25 | 0.21× | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 6.22× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流IIPRRIGL
| Q4 25 | $198.2M | $22.0M | ||
| Q3 25 | $45.6M | $24.0M | ||
| Q2 25 | $48.4M | $30.5M | ||
| Q1 25 | $54.2M | $-893.0K | ||
| Q4 24 | $258.4M | $14.5M | ||
| Q3 24 | $64.9M | $21.7M | ||
| Q2 24 | $64.2M | $302.0K | ||
| Q1 24 | $71.6M | $-5.0M |
现金转化率IIPRRIGL
| Q4 25 | 6.22× | 0.08× | ||
| Q3 25 | 1.56× | 0.86× | ||
| Q2 25 | 1.86× | 0.51× | ||
| Q1 25 | 1.75× | -0.08× | ||
| Q4 24 | 6.46× | 1.01× | ||
| Q3 24 | 1.61× | 1.75× | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
